
    
      To monitor the safety and efficacy of Modigraf® (tacrolimus granules) in stable paediatric
      allograft recipients (Part A) and to monitor dose changes and tacrolimus whole blood trough
      levels after conversion from a Modigraf based Immunosuppression regimen to a Prograf® based
      Immunosuppression regimen (Part B).
    
  